Humacyte, Inc. (HUMA)

↓ Download CSV

CIK 0001818382 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Humacyte, Inc. reported revenue of $2.04M. The company ran a net loss, with a net margin of -2003.6%. It held $116.37M in total assets against $113.26M in total liabilities.

Key ratios (FY2025)

-5306.0%
Operating margin
-2003.6%
Net margin
-1313.4%
Return on equity
Metric (FY)2025202420232022202120202019
Revenue$2.04M$0
Cost of Revenue$9.70M$0
Operating Income-$108.14M-$114.40M-$100.05M-$84.58M-$81.21M-$64.60M
Net Income-$40.83M-$148.70M-$110.78M-$11.96M-$26.48M-$66.52M
EPS (Diluted)$-0.26$-1.26$-1.07$-0.12$-0.66$-11.54
Total Assets$116.37M$137.87M$128.22M$204.30M$286.53M$106.69M
Total Liabilities$113.26M$190.54M$114.68M$87.37M$164.36M$36.02M
Shareholders' Equity$3.11M-$52.67M$13.55M$116.93M$122.17M-$350.32M-$288.79M
Cash & Equivalents$50.50M$44.94M$80.45M$149.77M$217.50M$39.93M
Operating Cash Flow-$105.04M-$98.12M-$73.31M-$71.13M-$81.19M-$55.57M
Capital Expenditures$884.0K$1.57M$2.28M$1.05M$220.0K$318.0K
Shares Outstanding193.00M130.03M103.67M103.23M103.00M5.82M